APTITUDE HEALTH®

EPICS

# EPICS CONGRESS COVERAGE: ASCO 2020 – FOCUS ON LUNG CANCER

June 2020

# BACKGROUND

EPICS

- On June 4, 2020, Aptitude Health brought together a group of experts in lung cancer to an expert panel

- The goal of the panel was to critique and debate evidence in lung cancer and gain strategic insight into the most impactful abstracts from the ASCO 2020 virtual meeting, with respect to shaping current research direction and/or changing the scope of practical clinical care

# MEET THE EXPERTS . . .

EPICS

Corey J. Langer, MD, FACP
University of Pennsylvania

Julie Brahmer, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD, USA

Enriqueta Felip, MD, PhD
Vall d'Hebron University Hospital
Barcelona, Spain

Nasser Hanna, MD
Indiana University School of Medicine
Indianapolis, IN, USA

Jyoti D. Patel, MD, FASCO
Northwestern University Feinberg School of Medicine
Evanston, IL, USA

Solange Peters, MD, PhD
University of Lausanne
Lausanne, Switzerland

David Spigel, MD
Sarah Cannon Research Institute
Nashville, TN, USA

# AGENDA

EPICS

| Time (EDT) | Topic | Speaker/Moderator |
|---|---|---|
| **12.00 PM** | Welcome and Introductions | Corey J. Langer, MD, FACP |
| **12.05 PM** | Immunotherapy: Stage IV NSCLC and Biomarker Research | Solange Peters, MD, PhD |
| **12.13 PM** | Discussion | All |
| **12.33 PM** | Key Takeaways | Corey J. Langer, MD, FACP |
| **12.38 PM** | Immunotherapy and Targeted Agents in Stage I–III NSCLC | Jyoti Patel, MD, Nasser Hanna, MD |
| **12.43 PM** | Discussion | All |
| **12.58 PM** | Key Takeaways | Corey J. Langer, MD, FACP |
| **1.03 PM** | Targeting Gene Fusions (*ALK, RET, NTRK*) | Enriqueta Felip, MD, PhD |
| **1.13 PM** | Discussion | All |
| **1.23 PM** | Key Takeaways | Corey J. Langer, MD, FACP |
| **1.28 PM** | Targeting Gene Mutations, Insertions, Amplifications (*EGFR, MET, HER2, KRAS*) | David Spigel, MD |
| **1.43 PM** | Discussion | All |
| **1.58 PM** | Key Takeaways | Corey J. Langer, MD, FACP |
| **2.03 PM** | **Break** | |
| **2.13 PM** | New Approaches in Non-Small Cell Lung Cancer | Julie Brahmer, MD |
| **2.18 PM** | Discussion | All |
| **2.28 PM** | Key Takeaways | Corey J. Langer, MD, FACP |
| **2.33 PM** | New Approaches in Small Cell Lung Cancer | Julie Brahmer, MD |
| **2.38 PM** | Discussion | All |
| **2.48 PM** | Key Takeaways | Corey J. Langer, MD, FACP |
| **2.53 PM** | Closing Remarks and Adjourn | Corey J. Langer, MD, FACP |

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (1/7)

EPICS

- 9500: Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (2/7)

EPICS

- 9501: Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (3/7)

EPICS

- 9503: Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (4/7)

- 9610: Cabozantinib in combination with atezolizumab in non-small cell lung cancer

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (5/7)

- 3518: Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (6/7)

EPICS

- 3046: Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH (7/7)

EPICS

- 9521: Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus

# IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH – DISCUSSION (1/5)

EPICS

## Clinical Trials

- The experts agreed that with multiple first-line combinations available, therapeutic

# IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH – DISCUSSION (2/5)

EPICS

## Clinical Trials

- The experts discussed potential applications for regimens containing nivolumab-

# IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH – DISCUSSION (3/5)

EPICS

## Clinical Trials

- The experts expressed enthusiasm for new approaches in immunotherapy

# IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH – DISCUSSION (4/5)

EPICS

## Clinical Trials

- Expert opinion is that the approval of single-agent atezolizumab in patients with PD-L1–

# IMMUNOTHERAPY: STAGE IV NSCLC AND BIOMARKER RESEARCH – DISCUSSION (5/5)

EPICS

## Biomarkers

- The experts generally think that neither TMB nor *STK11* status is currently ready for

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC (1/5)

EPICS

- LBA5: Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA *EGFR* mutation

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC (2/5)

EPICS

- 9005: CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC (3/5)

EPICS

- 9009: A phase I safety and feasibility study of neoadjuvant chemoradiation plus

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC (4/5)

EPICS

- 9016: SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant

# PROGRAM OVERVIEW: ABSTRACTS – IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC (5/5)

EPICS

- 9008: Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and

# IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC – DISCUSSION (1/4)

EPICS

## Resectable Disease

- The experts agreed that the ADAURA trial will be practice-changing, and that osimertinib

# IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC – DISCUSSION (2/4)

EPICS

## Resectable Disease

- For ADURO, the experts would like to see the data broken out by use of adjuvant

# IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC – DISCUSSION (3/4)

EPICS

## Resectable Disease

- The experts think results from ADAURA, together with the FLAURA trial demonstrating

# IMMUNOTHERAPY AND TARGETED AGENTS IN STAGE I–III NSCLC – DISCUSSION (4/4)

EPICS

## Unresectable Stage III NSCLC

- Experts await additional follow-up from the KEYNOTE 799 study investigating the addition

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK, RET, NTRK*) (1/6)

EPICS

## *ALK*

- 9518: Updated overall survival (OS) and safety data from the randomized, phase III ALEX

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK, RET, NTRK*) (2/6)

EPICS

## *ALK*

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK, RET, NTRK*) (3/6)

EPICS

## *RET*

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK, RET, NTRK*) (4/6)

EPICS

## *RET*

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK, RET, NTRK*) (5/6)

## *NTRK*

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE FUSIONS (*ALK, RET, NTRK*) (6/6)

EPICS

## *NTRK*

# TARGETING GENE FUSIONS (*ALK, RET, NTRK*) – DISCUSSION (1/2)

## *ALK*

- Alectinib and brigatinib are considered interchangeable in the first-line setting, but the

# TARGETING GENE FUSIONS (*ALK, RET, NTRK*) – DISCUSSION (2/2)

## *RET*

- With the recent approval of selpercatinib in patients with *RET* fusion-positive NSCLC, the

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) (1/10)

EPICS

## *EGFR*

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) (2/10)

EPICS

## *EGFR*

- 9512: Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) (3/10)

EPICS

## *EGFR*

- 9513: ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with *EGFR*

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) (4/10)

EPICS

## *EGFR*

- 9514: Poziotinib shows activity and durability of responses in subgroups of previously

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) (5/10)

EPICS

## *MET*

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) (6/10)

EPICS

## *MET*

- 9510: Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) (7/10)

EPICS

## *MET*

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) (8/10)

EPICS

## *MET*

- 9556: Primary efficacy and biomarker analyses from the VISION study of tepotinib in

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) (9/10)

EPICS

## *HER2*

- 9504: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with *HER2*-mutated

# PROGRAM OVERVIEW: ABSTRACTS – TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) (10/10)

EPICS

## *KRAS* (non-lung)

# TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) – DISCUSSION (1/3)

EPICS

## *EGFR*

- Experts discussed the recent US approval of ramucirumab-erlotinib for first-line therapy in

# TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) – DISCUSSION (2/3)

EPICS

## *EGFR*

- *EGFR* exon 20 insertions are typically refractory to EGFR TKIs (eg, poziotinib,

# TARGETING GENE MUTATIONS, INSERTIONS, AMPLIFICATIONS (*EGFR, MET, HER2, KRAS*) – DISCUSSION (3/3)

EPICS

## *MET*

- With the large number of MET inhibitors either approved or in development, there is a

# PROGRAM OVERVIEW: ABSTRACTS – NEW APPROACHES IN NON-SMALL CELL LUNG CANCER (1/2)

EPICS

> 9505: Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients

# PROGRAM OVERVIEW: ABSTRACTS – NEW APPROACHES IN NON-SMALL CELL LUNG CANCER (2/2)

EPICS

- 3100: Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or

# NEW APPROACHES IN NON-SMALL CELL LUNG CANCER – DISCUSSION

EPICS

- Regarding the development of new agents, the experts pointed out that response rate in

# PROGRAM OVERVIEW: ABSTRACTS – NEW APPROACHES IN SMALL CELL LUNG CANCER (1/3)

EPICS

- 9001: KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum

# PROGRAM OVERVIEW: ABSTRACTS – NEW APPROACHES IN SMALL CELL LUNG CANCER (2/3)

EPICS

- 9002: Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage

# PROGRAM OVERVIEW: ABSTRACTS – NEW APPROACHES IN SMALL CELL LUNG CANCER (3/3)

EPICS

- 9068: First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC

# NEW APPROACHES IN SMALL CELL LUNG CANCER – DISCUSSION (1/2)

EPICS

- The US-based experts currently use atezolizumab with chemotherapy as first-line therapy

# NEW APPROACHES IN SMALL CELL LUNG CANCER – DISCUSSION (2/2)

- The experts briefly discussed the press release regarding the CheckMate 743 trial in

APTITUDE HEALTH®

**US Headquarters**
5901-C Peachtree Dunwoody Road NE
Suite 200, Atlanta, GA 30328, US

**EU Headquarters**
Wilhelmina van Pruisenweg 104
2595 AN The Hague, the Netherlands

**aptitude-health.com**